Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sclerosing cholangitis.

George R MacFaul1, Roger W Chapman

  • 1Department of Gastroenterology, John Radcliffe Hospital, Oxford, UK.

Current Opinion in Gastroenterology
|March 22, 2006
PubMed
Summary
This summary is machine-generated.

Primary sclerosing cholangitis (PSC) is an immune-mediated liver disease. While liver transplantation is the only established long-term treatment, new insights suggest autoimmune pancreatitis may be misdiagnosed as PSC.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Determining the time to cholangiocarcinoma in pediatric-onset PSC-IBD.

Journal of pediatric gastroenterology and nutrition·2024
Same author

Dye-based chromoendoscopy detects more neoplasia than white light endoscopy in patients with primary sclerosing cholangitis and IBD.

Endoscopy international open·2024
Same author

Primary sclerosing cholangitis-A long night's journey into day.

Clinical liver disease·2022
Same author

Prevalence and long-term outcome of sub-clinical primary sclerosing cholangitis in patients with ulcerative colitis.

Liver international : official journal of the International Association for the Study of the Liver·2020
Same author

Review of primary sclerosing cholangitis with increased IgG4 levels.

World journal of gastroenterology·2020
Same author

Experience from the first UK inter-regional specialist multidisciplinary meeting in the diagnosis and management of IgG4-related disease.

Clinical medicine (London, England)·2020
Same journal

Endoscopic techniques to minimize gastroesophageal reflux during peroral endoscopic myotomy.

Current opinion in gastroenterology·2026
Same journal

Postendoscopy esophageal adenocarcinoma and neoplasia: current status and future directions.

Current opinion in gastroenterology·2026
Same journal

The complement system in inflammatory bowel disease: from early observations to emerging frontiers.

Current opinion in gastroenterology·2026
Same journal

Goblet cell-associated antigen passages in health and disease.

Current opinion in gastroenterology·2026
Same journal

Inflammatory bowel diseases 2026: form, function and therapeutic considerations for the epithelial barrier.

Current opinion in gastroenterology·2026
Same journal

Dietary protein as a regulator of colitis and colorectal cancer.

Current opinion in gastroenterology·2026
See all related articles

Area of Science:

  • Hepatology
  • Immunology
  • Gastroenterology

Background:

  • Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease with unknown etiology.
  • It involves biliary tree strictures, cirrhosis, and cholangiocarcinoma.
  • PSC is considered immune-mediated.

Purpose of the Study:

  • To review current research on PSC etiopathogenesis and epidemiology.
  • To discuss the relationship between PSC and inflammatory bowel disease (IBD).
  • To evaluate diagnostic and therapeutic strategies for PSC and its complications.

Main Methods:

  • Literature review of recent research on PSC.
  • Analysis of studies on diagnosis, medical therapy, and liver transplantation outcomes.
  • Discussion of emerging concepts in PSC classification and management.

Related Experiment Videos

Main Results:

  • Some PSC cases may be autoimmune pancreatitis with distinct features.
  • PSC-IBD may represent a unique IBD phenotype requiring specific surveillance.
  • CA19-9 is not effective for cholangiocarcinoma surveillance.
  • Ursodeoxycholic acid shows limited impact on PSC progression.
  • Orthotopic liver transplantation is the only definitive long-term treatment for PSC.

Conclusions:

  • Re-evaluation of PSC diagnoses may identify associated autoimmune pancreatitis.
  • PSC-IBD warrants distinct management and surveillance protocols.
  • Current medical therapies, including ursodeoxycholic acid, have not significantly altered PSC outcomes.
  • Liver transplantation remains the gold standard for advanced PSC.